Tirzepatide dosage: the standard titration schedule explained

If you've been researching tirzepatide, you've probably seen numbers like 2.5 mg, 5 mg, 10 mg, and 15 mg scattered across different sources with little explanation of what they mean or why they matter. This guide walks you through the standard titration schedule, the biology behind it, and what the clinical evidence actually shows at each dose level — so you can have an informed conversation with a provider rather than piecing things together from forum posts.

Why tirzepatide dosing starts low and increases gradually

Tirzepatide is a dual GIP and GLP-1 receptor agonist. That means it activates two hormonal pathways simultaneously — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both receptors are found in the brain regions that regulate appetite and what researchers call 'food noise' — the relentless mental chatter about what to eat next, when to eat, and whether you've eaten too much. If that internal noise has been loud for years, it's not a character flaw. It reflects how these hormonal signals are — or aren't — working in your brain. Tirzepatide works at the biological level to quiet that signal.

Because the medication is pharmacologically active at relatively low doses, starting at the full therapeutic dose would overwhelm your GI tract. Nausea, vomiting, and constipation — the most commonly reported side effects in clinical trials — are significantly more manageable when the dose escalates slowly, giving your body time to adapt. This is not a loophole or a workaround; it is the intended design of the dosing protocol.

The standard tirzepatide titration schedule

The titration schedule used in the SURMOUNT clinical trials — and reflected in the FDA-approved dosing for brand-name products Zepbound and Mounjaro — follows a stepwise four-week interval between each dose increase. Compounded tirzepatide, prepared by a US-licensed compounding pharmacy under a valid prescription, is not an FDA-approved finished product, but providers prescribing it typically follow the same evidence-based titration framework because the underlying pharmacology is identical to the tirzepatide molecule studied in trials.

• Weeks 1-4: 2.5 mg once weekly. This is the starting dose. Its purpose is tolerability, not significant weight loss. Most people experience minimal side effects at this level.
• Weeks 5-8: 5 mg once weekly. This is the first maintenance-eligible dose. Some patients feel a meaningful reduction in appetite here. In trials, patients at 5 mg began showing measurable weight reduction.
• Weeks 9-12: 7.5 mg once weekly. The mid-range escalation. GI side effects, if they appear, most commonly emerge during upward titration steps — especially this one and the next.
• Weeks 13-16: 10 mg once weekly. For many patients, this dose produces substantial appetite suppression and continued weight loss.
• Weeks 17-20: 12.5 mg once weekly. The second-to-last step in the standard schedule.
• Week 21 onward: 15 mg once weekly. The maximum dose studied in SURMOUNT-1. Not everyone reaches or needs this dose — your provider determines the appropriate maintenance level based on your response and tolerability.

Each four-week window is intentional. It takes time for your body to reach steady-state plasma levels at a given dose, and it takes time for side effects to resolve if they appear. Rushing the schedule to get faster results is not supported by the evidence and increases the likelihood of nausea severe enough to cause you to stop the medication altogether.

What the clinical evidence shows at the 15 mg dose

The most cited data comes from SURMOUNT-1 (Jastreboff et al., NEJM 2022), a randomized controlled trial of tirzepatide in adults with obesity or overweight plus at least one weight-related comorbidity. Participants who reached the 15 mg dose achieved a mean body-weight reduction of approximately 20.9% over 72 weeks. That figure is from a clinical trial of the tirzepatide molecule — it does not reflect StaveMD patient outcomes, and individual outcomes vary based on starting weight, adherence, diet, activity level, and biology.

SURMOUNT-5, a head-to-head trial comparing tirzepatide with semaglutide, found a mean weight reduction of approximately 20.2% with tirzepatide versus 13.7% with semaglutide over 72 weeks. Again, these are molecule-level clinical trial results, not guaranteed outcomes for any individual patient.

It's also worth understanding why weight loss stalls over time and why stopping medication often leads to regain. Research from the NIH 'Biggest Loser' study (Fothergill et al., 2016) documented that sustained caloric restriction triggers lasting metabolic adaptation — your resting metabolic rate drops significantly and does not fully recover even years later. This is your biology defending a set point, not evidence that you failed. Tirzepatide does not fix metabolic adaptation entirely, but it does reduce the appetite-driven pressure that makes adhering to a caloric deficit so difficult in the first place.

Side effects to know before you start

The most common side effects reported across SURMOUNT trials are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are most likely to occur during dose escalation steps and typically improve within a few weeks at a stable dose. Eating smaller meals, avoiding high-fat foods around the time of injection, and staying well-hydrated can reduce their severity.

• Nausea: the most frequently reported side effect, particularly at higher doses and during titration steps.
• Diarrhea or constipation: both are reported; constipation tends to be more common at steady state.
• Injection-site reactions: mild redness or discomfort at the injection site, generally self-limiting.
• Reduced appetite: often dramatic, which is the intended mechanism — but it can occasionally make adequate protein and nutrient intake harder to maintain without deliberate attention.
• Rare but serious risks: tirzepatide carries a boxed warning for thyroid C-cell tumors based on animal studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. A provider will review your history before prescribing.

If side effects are severe or persistent at any dose step, the standard clinical approach is to pause titration — or in some cases to step back to the previous dose — rather than push through. This is a conversation to have with your prescribing provider, not a decision to make on your own.

Compounded tirzepatide versus FDA-approved brand-name products

Zepbound and Mounjaro are FDA-approved finished drug products containing tirzepatide. Compounded tirzepatide is prepared by a US-licensed compounding pharmacy under a valid provider prescription and is not an FDA-approved finished product. StaveMD does not compound or manufacture medication. When you fill a prescription through StaveMD, the medication is prepared by a licensed compounding pharmacy operating under applicable federal and state pharmacy law. The active molecule — tirzepatide — is the same molecule studied in SURMOUNT and SURPASS trials. The clinical trial data cited throughout this article reflects research on that molecule, not on compounded formulations specifically, and not on any StaveMD patient population.

Pricing for compounded tirzepatide is often substantially lower than brand-name alternatives, which is why many patients pursue this route. StaveMD is transparent about costs upfront — what you see is what you pay, with no bait-and-switch pricing after your first month.